Full Text Full Text (PDF) Citation Map Email this article to a Colleague Similar articles in this journal Alert me to new issues of the journal Add to My Articles & Searches Download to citation manager Citing Articles via HighWire Citing Articles via Google Scholar Articles by Rifai, M. A. Articles by Rosenstein, D. L. Search for Related Content Articles by Rifai, M. A. Articles by Rosenstein, D. L.

Hepatitis C and Psychiatry

Correspondence: Send reprint requests to Dr. Rifai, National Institute of Mental Health, 10 3N-240, Bethesda, MD 20892-1276; e-mail, AlyRifai{at}mail.nih.gov.

Approximately 4 million Americans are chronically infected with the hepatitis C virus (HCV). Compared with the general U.S. population, patients with HCV have a higher prevalence of psychiatric illness, and patients with severe mental illness have four to nine times the prevalence of HCV. The use of interferon-alpha (IFN) to eradicate HCV has been associated with frequent neuropsychiatric adverse effects (e.g., affective, anxiety, cognitive, and psychotic symptoms) that compromise the management of HCV patients with and without a preexisting history of psychiatric illness. Psychiatric symptoms often result in the interruption, dose reduction, or cessation of IFN therapy, which makes treatment of patients with comorbid HCV and psychiatric illness a challenge. IFN can be safely administered to psychiatric patients with HCV but requires a comprehensive pretreatment assessment, a risk-benefit analysis, and ongoing psychiatric follow-up. This review summarizes the psychiatric implications of HCV infection and strategies for the management of IFN-induced neuropsychiatric adverse effects.

This article has been cited by other articles:

				M. A. Rifai, J. K. Moles, and D. D. Short Hepatitis C Treatment Eligibility and Outcomes Among Patients With Psychiatric Illness Psychiatr Serv, April 1, 2006; 57(4): 570 - 572. [Abstract] [Full Text] [PDF]

				M. A. Rifai, J. K. Moles, L. P. Lehman, and B. J. Van der Linden Hepatitis C screening and treatment outcomes in patients with substance use/dependence disorders. Psychosomatics, March 1, 2006; 47(2): 112 - 121. [Abstract] [Full Text] [PDF]

Get information about faster international access.

Privacy Policy

Copyright © 2005 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us